Key result
In patients undergoing post-cardiotomy ECMO with bivalirudin anticoagulation, intracardiac blood stagnation should be avoided to limit the risk of spontaneous intracardiac thrombosis.
Why the study?
Does bivalirudin anticoagulation pose a risk of intracardiac thrombus formation in patients under ECMO with blood stagnation?
Does bivalirudin anticoagulation pose a risk of intracardiac thrombus formation in patients under ECMO with blood stagnation?
No takes yet. Share an insight, caveat, or question.
When using bivalirudin for anticoagulation during ECMO, maintaining minimal intracardiac blood flow is recommended to prevent intracardiac thrombosis in areas of blood stagnation.
Marco Ranucci (2012) conducted a letter in Post-cardiotomy extracorporeal membrane oxygenation (ECMO) (n=20). Bivalirudin vs. Standard heparin anticoagulation was evaluated on Risk of intracardiac thrombosis. In patients undergoing post-cardiotomy ECMO with bivalirudin anticoagulation, intracardiac blood stagnation should be avoided to limit the risk of spontaneous intracardiac thrombosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: